Outcomes of Adolescent LBCL Patients Treated With Adult Type Chemotherapy: A Single Center Experience.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Lymphoma is the most common cancer in adolescents. Outcome disparities based on the locus of care are increasingly recognized in this age group. MATERIALS AND METHODS: We report outcomes of LBCL patients between 14 and 21 who were treated at an adult center using adult type chemotherapy. RESULTS: Sixty-four patients, median age 19 were analyzed. 82.8% were DLBCL, 17.2% were PMBCL; 21.9% stage I, 31.3% stage II, 7.8% stage III, and 39 % stage IV; 18.8% "very good", 62.5% "good" and 18.8% "poor" RIPI score. The median follow-up period was 68.8 months. The 5 years OS was 94.3%, and the 5 years EFS was 78.3%. High RIPI patients had a worse OS. High RIPI, B symptoms, ABC cell of origin and PMBCL had worse EFS. CONCLUSION: Pediatric protocol use should be restricted to patients at higher risk of events rather than to all these patients.